TrovaGene Unternehmenskultur

Dr. Mark Erlander, Ph.D., has been the Chief Scientific Officer of TrovaGene, Inc. since March 4, 2013. Dr. Erlander directs the clinical development program for the portfolio of transrenal and urine-based molecular diagnostic assays. He served as Chief Scientific Officer of BioTheranostics, Inc., (Formerly, Arcturus Bioscience Inc) since 2000. He served as Vice President of BioTheranostics, Inc. He has more than 18 years of experience directing research teams with a strong focus in oncology-based molecular diagnostics. He has developed multiple novel molecular diagnostic assays from biomarker discovery to test commercialization, notably CancerTYPE ID(R) and Breast Cancer Index(SM). Dr. Erlander has overseen a significant portfolio of retrospective and prospective clinical studies to establish both clinical validity and utility of these tests. He serves as a Member of Clinical Advisory Board at DioGenix, Inc. Prior to joining BioTheranostics, Inc. in 2000, he was Research Fellow, Head of Genomics, at R.W. Johnson Pharmaceutical Research Institute, where he directed 20 scientists responsible for applying genomics to the drug discovery process, including target identification, compound toxicity and clinical trails. Prior to his time at Johnson & Johnson, Dr. Erlander was an Assistant Member and postdoctoral fellow at The Scripps Research Institute in the Department of Molecular Biology. He holds 38 issued U.S. patents in the areas of diagnostics, therapeutics and genomic technologies and is an author of 73 scientific publications with 56 peer-reviewed original articles and 17 review/chapter publications. He graduated with a BS degree in Biochemistry from the University of California, Davis and an MS degree in Biochemistry from the Iowa State University in Ames, Iowa. Dr. Erlander received his Ph.D. in Neuroscience from the University of California, Los Angeles.

Ms. Elizabeth Anderson, CPA, also known as Beth, has been a Vice President of Finance and Administration at TrovaGene, Inc. since July 2015. Ms. Anderson's responsibilities include administration of accounting, SEC reporting, financial planning, treasury and human resources. Ms. Anderson has over 20 years of financial, venture capital, corporate acquisition and operations experience in the life sciences industry. She served as the Senior Director of Finance and Administration at Neothetics, Inc, where she was an integral part of multiple rounds of private financing and a successful initial public offering. Previously, Ms. Anderson held senior financial positions at Awarepoint, GenVault, Kalypsys and Sequenom. Ms. Anderson served as Director of Finance and Administration at Kalypsys, Inc. Prior to Joining Kalypsys, Ms. Anderson was with Sequenom, Inc. since July 1998 and served as its Vice President of Finance and held broad responsibilities in finance, accounting, treasury and corporate governance, in addition to overseeing Facilities and Logistics since 2001. Ms. Anderson began her career with Ernst & Young LLP., where she worked with San Diego high technology and biotechnology companies and assisted many multi-national companies in completing mergers and acquisitions in Italy. She has a B.S. in Business Administration and Accounting from Colorado State University and is a Certified Public Accountant.

Vicki Kelemen serves as the Senior Director Strategic Enagagement and Communications of Trovagene, Inc.. Vicki currently resides in the Greater San Diego Area.